CORVUS PHARMACEUTICALS INC (CRVS) Stock News
NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock
CRVS Latest News and Analysis
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo...
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today...
Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released interim data from a Phase 1 trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. The trial will enroll 64 patients with moderate to severe atopic dermatitis who previously failed one prior topical or systemic therapy. These doses were selected based on the company’s prior experience evaluating soquelitinib in T-cell lymphoma patients. The company is reporting complete results from Cohort 1 of the trial, which inc
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024
Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. ...
Relative Strength Alert For Corvus Pharmaceuticals
Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity
Data published in peer-reviewed npj Drug Discovery, a Nature portfolio journal...
Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis
Adds to growing body of evidence supporting the potential of ITK inhibition as a novel therapeutic for the treatment of a wide range of immune diseases ...
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial...
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected as a top 100 abstract...
Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma
Soquelitinib is a potential first-in-class ITK inhibitor with broad potential in cancer and immune diseases There are currently no fully approved agents...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BURLINGAME, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
Early Results from Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Demonstrate Clinical Activity and Corresponding Changes in Cytokine Levels...
Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need...
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
The 2024 Millionaire’s Club: 3 Penny Stocks to Buy Now
One of the best ways to spot opportunity in penny stocks to buy is by following insiders. Here are three to consider.
Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference
BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today...
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
CRVS stock results show that Corvus Pharma missed analyst estimates for earnings per share the first quarter of 2024.
CRVS Stock Earnings: Corvus Pharma Misses EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Corvus Pharma (NASDAQ:CRVS) just reported results for the first quarter of 2024...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Soquelitinib Phase 1 Randomized Trial in Atopic Dermatitis Enrolling at Multiple Centers; Potential for Early Data Before Year-End 2024 Soquelitinib...
Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT...
Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering
BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a...